DAK-AMNOG Report 2023
01.03.2023 13:25
“The results of the AMNOG report 2023 show what was already widely suspected in the fall of last year: the planned AMNOG measures, in particular the retroactive effect of the reimbursement amount and the lowering of the orphan drug threshold, generate minor additional savings, but do not solve any structural ones problems.
Key implementation questions remain open and the savings expectations formulated in the Financial Stabilization Act are associated with a high degree of uncertainty. There must therefore be further development and not an AMNOG moratorium for the rest of the electoral period. There should be an evaluation next year, which must be followed by a real amendment to AMNOG that addresses the structural problems in the long term,” says Andreas Storm, Chairman of the Board of DAK-Gesundheit.
GKV-FinStG just an intermediate step?
Based on the available results, it is not unlikely that this is the case GKV-FinStG is only an intermediate step towards further AMNOG reform. The Implementation of the combination discount could – if pragmatic is lacking Willingness of the contractual partners to find a solution – further legislative intervention requireddern. This also applies if it becomes apparent that the complexity of AMNOG guard rails for pricing are not the desired ones, but rather a collateral effectte would bring with them. A planned evaluation will show this. But there would also be There are still open issues, for example the challenges in pricing many novel gene therapies, which are so-called one-off therapies that have not yet been solved Challenges in fair pricing bwould struggle, according to the DAK's assessment.
For the Download of the entire report.